http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108727222-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C41-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C41-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C253-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C255-37 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C253-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-277 |
| filingDate | 2017-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108727222-B |
| titleOfInvention | TYD1608 with selective anticancer activity and preparation and application thereof |
| abstract | The invention provides cyano-containing TYD1608, namely (Z) -3- (p-methylphenyl) -2- (3, 4, 5-trimethoxyphenyl) acrylonitrile, and a preparation method and application thereof, and relates to the field of medicinal compounds, wherein the structure of the cyano-containing TYD1608 is shown as follows: at present, many anticancer drugs not only have killing capacity on cancer cells, but also have high toxicity on normal cells, and seriously affect the treatment of cancer patients, so that the development of a selective anticancer active drug safe to the normal cells is particularly important. The compound has very strong proliferation inhibiting capacity on 6 kinds of human cancer cells and very weak toxicity on normal human liver cells of L-02. Its IC against MGC-803 gastric cancer cells 50 The value is less than 0.01 mu M, is stronger than the clinical common anticancer drug taxol, and has good selective anticancer activity. Mechanistic studies have shown that the proliferative inhibitory activity of TYD1608 on BEL-7402 cancer cells is a result of inhibition of the G2/M phase of the cell cycle, induction of early and late apoptosis, inhibition of cell migration, inhibition of the cell cycle-associated proteins cyclin A1 and cyclin D1. |
| priorityDate | 2017-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 125.